The post Leap Therapeutics Gains 25% on Crypto Deal appeared on BitcoinEthereumNews.com. Shares of Leap Therapeutics (LPTX) climbed 25% after the microcap cancer drug developer announced a $58.9 million private investment led by Winklevoss Capital to kickstart a crypto treasury strategy. The investment, structured as a private placement, includes common shares and warrants priced at $0.61439 per unit. Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will also gain two board seats at Leap. Exactly which cryptos would be purchased was not disclosed. Leap, known for its immuno-oncology therapies, said it will use a portion of the capital to purchase cryptocurrency as part of a longer-term plan to hold crypto on its balance sheet. The rest will support clinical development of its drug candidates. The deal places Leap among a growing list of public companies using crypto as a treasury reserve. Leap said more details on its digital asset strategy will be announced in the near future and didn’t detail which assets it plans on acquiring. Shares were higher by 25% in Monday morning trade. Source: https://www.coindesk.com/markets/2025/10/06/leap-therapeutics-shares-jump-on-usd59m-winklevoss-led-crypto-dealThe post Leap Therapeutics Gains 25% on Crypto Deal appeared on BitcoinEthereumNews.com. Shares of Leap Therapeutics (LPTX) climbed 25% after the microcap cancer drug developer announced a $58.9 million private investment led by Winklevoss Capital to kickstart a crypto treasury strategy. The investment, structured as a private placement, includes common shares and warrants priced at $0.61439 per unit. Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will also gain two board seats at Leap. Exactly which cryptos would be purchased was not disclosed. Leap, known for its immuno-oncology therapies, said it will use a portion of the capital to purchase cryptocurrency as part of a longer-term plan to hold crypto on its balance sheet. The rest will support clinical development of its drug candidates. The deal places Leap among a growing list of public companies using crypto as a treasury reserve. Leap said more details on its digital asset strategy will be announced in the near future and didn’t detail which assets it plans on acquiring. Shares were higher by 25% in Monday morning trade. Source: https://www.coindesk.com/markets/2025/10/06/leap-therapeutics-shares-jump-on-usd59m-winklevoss-led-crypto-deal

Leap Therapeutics Gains 25% on Crypto Deal

Shares of Leap Therapeutics (LPTX) climbed 25% after the microcap cancer drug developer announced a $58.9 million private investment led by Winklevoss Capital to kickstart a crypto treasury strategy.

The investment, structured as a private placement, includes common shares and warrants priced at $0.61439 per unit. Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will also gain two board seats at Leap.

Exactly which cryptos would be purchased was not disclosed.

Leap, known for its immuno-oncology therapies, said it will use a portion of the capital to purchase cryptocurrency as part of a longer-term plan to hold crypto on its balance sheet. The rest will support clinical development of its drug candidates.

The deal places Leap among a growing list of public companies using crypto as a treasury reserve. Leap said more details on its digital asset strategy will be announced in the near future and didn’t detail which assets it plans on acquiring.

Shares were higher by 25% in Monday morning trade.

Source: https://www.coindesk.com/markets/2025/10/06/leap-therapeutics-shares-jump-on-usd59m-winklevoss-led-crypto-deal

Market Opportunity
GAINS Logo
GAINS Price(GAINS)
$0.01213
$0.01213$0.01213
-2.01%
USD
GAINS (GAINS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.